Search Results

September 2022 Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model antibody atezolizumab and nab-paclitaxel has shown clinical activity in advanced TNBC with PD-L1-positive tumor-infiltrating As tumor-associated macrophages (TAMs) serve as major contributors to the immuno-suppressive tumor microenvironment We show that through proper calibration, the model captures the macrophage heterogeneity in the tumor

and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors

Here, using colorectal cancer (CRC) as a model, we explored the gene expression of a panel of GPCRs in tumor live-imaging modalities, and displayed high efficiency when used to label complex 3D cellular systems such as tumor A2BAR as a potential pharmacological tool in CRC, using selective antagonists, finding a reduction in tumor

PAR4 emerges as a potent oncogene, capable of inducing tumor generation. attenuates PAR2&4-Akt/PKB associations; PAR4 instigated Matrigel invasion and migration in vitro and tumor We propose that Pc(4-4) may serve as a powerful drug not only toward PAR-expressing tumors but also for treating EGFR/erbB-expressing tumors in cases of resistance to traditional therapies.

(CCR9), an organ-specific chemokine receptor, interacts with its exclusive ligand CCL25 to promote tumor Immunohistochemistry staining and RT–qPCR analyses were performed to detect the correlation of CCR9 expression and tumor The effect of CCL25 on the development of SACC in vivo was examined by a xenograft tumor model in nude

Indeed, EZH2 is found to be directly correlated with high PAR4-driven tumors, and is abundantly expressed in large tumors, whereas very little to almost none is expressed in small tumors.

Additionally, CXCR4 is expressed by tumor cells in blood malignancies and solid tumors."

Gene Expression Omnibus (GEO) data, our analysis revealed that (a) RGS20 was strongly upregulated in tumor RGS20 was strongly associated with some important clinical parameters such as alpha-fetoprotein and tumor serous cystadenocarcinoma: p = 0.048); (d) RGS20 was found to be significantly associated with some tumor-related

high-impact mutations at cognate structural positions in class A G protein-coupled receptors expressed in tumors than effectors, mutations in different receptors could perturb signaling similarly so as to favor a tumor We hypothesized that somatic mutations in tumor samples may not be enriched within a single gene but that recurrent impactful oncogenic mutations perturb different GPCRs to subvert signaling and promote tumor

In CRPC xenografts, antagonizing AVPR2, AVPR1A, or both significantly reduced CRPC tumor growth as well as decreased on-target markers of tumor burden.

diseases (Proudfoot 2002), and in recent years attention has increasingly focused on cancer, where tumors chemokine system to provide growth and survival signals, establish and maintain an immunosuppressive tumor Redundancy can be exemplified by the tumor infiltration of Treg cells which can be driven directly by

September 2022 "For decades, glioblastoma multiforme (GBM), a type of the most lethal brain tumor, has

Somatostatin receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent somatostatin receptor type 2 (SST2) and 5 (SST5) and regulates their expression and signaling in pituitary tumoral

development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors

Materials: In our study, we compared GPR39 expression between colon cancers and tumor-adjacent tissues

development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors

with transcriptomic analysis revealing that while the majority of cancer cells express multiple ORs, tumor directed towards an OR could either drive receptor inactivation or activation of the receptor to destroy tumor The chimeric antigen receptor T cell therapy could also be a way to target tumor cells expressing ectopic

In this review, we discuss both the ‘friend’ and ‘foe’ features of TGR5 by summarizing its tumor-suppressing

Insights into MRP3 Transporter Function "Glioblastoma is the most common and aggressive primary brain tumor

development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors

cells, such as inhibition of cell proliferation, colony formation, migration, invasion and xenograft tumor

the worse survival in patients with lymph node metastasis, TNM stage III as well as nuclear grade G3 tumors

GPR4 in the pH-dependent migration of melanoma cells in the tumor microenvironment. dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors

Glioma is the most common adult malignant brain tumor and requires novel therapeutic strategies to improve

GPCRs in Oncology and Immunology G protein-coupled receptor-mediated signaling of immunomodulation in tumor

Convergent substitutions and recurrent gene loss in sauropsids Noval insights and therapeutic strategies for tumor-induced

complex in living cells GPCRs in Oncology and Immunology Metabolic crosstalk: Extracellular ATP and the tumor

under suboptimal conditions Exploiting frequent and specific expression of PRL3 in pediatric solid tumors